In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - COG-ANHL2121
Protocol Summary
- Protocol No
- COG-ANHL2121
- Principal Investigator
- Peter Shaw
- Phase
- II
- Title
- Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
- Associated Disease(s)
-
Other Solid Tumor
- Description (Summary)
- This study looks at how well tovorafenib (DAY101) works when given to children and young adults with relapsed or refractory Langerhans cell histiocytosis. Tovorafenib (DAY101) is experimental because it has not been proven to work in a situation like yours.
Although tovorafenib (DAY101) is investigational, it has been shown to be well-tolerated in children and adults.
Tovorafenib (DAY101) has already been approved by the FDA to treat other cancers known as low-grade gliomas in children.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
